Described herein is protective gear to protect against infectious agents and an analytical method for determining the presence of an infectious agent. The analytical method uses sample collected from air, in particular exhaled breath, to determine the presence of an infectious agent in such air or breath sample.
Described herein is a bioinformatic method for determining the presence of viral contamination in a sample and if such viral contamination is present the identification of the type(s) of contamination. The method uses high throughput sequencing techniques on DNA and/or RNA present in a sample. The methods described herein facilitate in-process control and r processing for release of batches, cell banks, bulk harvest and raw materials.
The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGFβ inhibitor, and an adenosine inhibitor to treat cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
5.
METHOD FOR GLYCOSYLATION PROFILING TO DESCRIBE FUNCTIONAL CHARACTERISTICS OF A BIOLOGIC MOLECULE
The glycosylation profile of a biologic molecule describes important aspects of such biologic molecule. The characterization of the glycosylation profile of a biologic molecule is an important part of the critical quality attributes in the manufacturing and analytical processes for biologic molecules. As such described herein are methods to determine and characterize the glycosylation profile of a biologic molecule. In particular, the method uses one or more indices to describe the glycosylation profile as a finger-print of such biologic molecule.
The invention relates to the field of protein purification processes involving several chromatography steps. The invention pertains to a method for purifying a protein, preferably an antibody or fragment thereof or a protein containing said fragment, from a complex solution, wherein said method comprises at least two chromatography steps which are performed using buffers comprising or consisting of the same chemical compounds. The invention is particularly useful for large scale production and purification of recombinant proteins.
The present disclosure relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGF-beta inhibitor, and a MCT4 inhibitor to treat cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
The present disclosure relates to combination therapies useful for the treatment of cancer. In particular, the disclosure relates to the combined use of a PD-1 inhibitor, a TGFbeta inhibitor, and a PARP inhibitor to treat cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
10.
NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
The present invention encompasses NHE-1 inhibitors for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
Described herein is dispensing cup for use with medicaments, which dispensing cup in use allows for the patient to (self) administer an oral medicament (tablet or capsule) without the need to come into direct (skin) contact with such medicament.
A61J 1/03 - Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
A61J 7/00 - Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
B65D 83/04 - Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, or spherical or like small articles, e.g. tablets or pills
The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGFβ inhibitor, and a VEGF inhibitor to treat cancer.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
13.
COMBINATION TREATMENT FOR CANCER BASED UPON AN ICOS ANTIBODY AND A PD-L1 ANTIBODY TGF-BETA-RECEPTOR FUSION PROTEIN
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (United Kingdom)
ARES TRADING S.A. (Switzerland)
Inventor
Ballas, Marc S.
Ellis, Catherine E.
Hirschfeld, Steven
Abstract
The invention relates to a method of treating cancer, involving the combination of an ICOS binding protein, a PD-1 inhibitor and a TGF-β inhibitor. In particular, the invention relates to an ICOS binding protein (e.g. an anti-ICOS antibody) and a fusion protein targeting human protein Programmed Death Ligand 1 (PD-L1) or Programmed Cell Death Protein 1 (PD-1), and Transforming Growth Factor β (TGF-β) (e.g. an anti-PD-(L)1(IgG):TGFβR fusion protein, comprising, for example, an anti-PD-L1 antibody and a TGFβRII or a fragment capable of binding to TGF-β).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
The invention described herein relates to an improved method for analytical capillary gel electrophoresis (CGE) for complex biologic molecules. The methods for the improved CGE include steps for the partial reduction of the biologic analyte molecule for use as calibration standard and use such partially reduced calibration sample to obtain an improved calibration curve for CGE to be used with biologic analyte molecules.
The present invention relates to a pharmaceutical composition, particularly a pharmaceutical composition comprising an IgG:TGFβRII (such as an anti-PD-L1:TGFβ-inhibiting) fusion protein. The present invention also relates inter alia to a method of manufacturing the composition, to a kit including the composition, to a package including the composition, to a method of manufacturing the package, and to methods of treatment using the composition and/or package, especially cancer treatments.
Transdermal drug delivery devices are described herein such as a microneedle array patch, to be placed on the skin for transdermal delivery of a medicament. The transdermal drug delivery device for delivery of a bioactive agent through mammalian skin comprises an array of microneedles and a means to actuate the microneedles, wherein the actuation means actuates the microneedles separately.
The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGFβ inhibitor, an ATM inhibitor and radiation to treat cancer.
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Described herein is a home stock management system (1) for packaged items comprising a stationary data collection module (10) configured to wirelessly collect data from one or more packaged items (11) and to transmit the collected data to a processing module (12) wherein the packaged item(s) (11) include(s) a wireless tag (15), a processing module (12) for receiving, storing and processing the collected data from the collection module (10), and a notification means (13), wherein, the data collection module (10) is configured to collect data from the one or more packaged items (11) present in the home without user intervention. The processing module (12) is configured to process the collected data to determine status information and the notification means (13) is configured to communicate to one or more authorized users the status information. The home stock management system (1) can be used for the monitoring of consumable packaged items in the house or for monitoring and managing the stock and use of medication in a patient home or residence.
The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Systems disclosed herein provide for a disposal cabinet for discarding and identifying a variety of injection devices. Embodiments provide for the identification of the injection device based on at least one color and shape of the injection device. The identification of the injection device is performed with a plurality of decision trees. The injection devices are safely and efficiently 5 discarded into a disposal container located within the disposal cabinet.
A61B 50/36 - Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments for collecting or disposing of used articles
A61B 90/90 - Identification means for patients or instruments, e.g. tags
A61B 90/92 - Identification means for patients or instruments, e.g. tags coded with colour
There is described a communication system (1) comprising a central unit (3) and a communication element (20). The central unit (3) comprises at least one RF antenna (4), a transmitter (6) configured to transmit a RF signal and a receiver (8) configured to receive a backscattered RF signal. The communication element (20) comprises a RF antenna (22) and a modulator (23) configured to backscatter the RF signal. The communication element (20) comprises a means for modulating the backscattered RF signal into a spread spectrum backscattered RF signal, and a means for supplying power.
G06K 19/07 - Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards with integrated circuit chips
G06K 19/077 - Constructional details, e.g. mounting of circuits in the carrier
H04B 1/707 - Spread spectrum techniques using direct sequence modulation
G06Q 10/08 - Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
G06K 7/00 - Methods or arrangements for sensing record carriers
H01Q 1/22 - Supports; Mounting means by structural association with other equipment or articles
H04B 5/00 - Near-field transmission systems, e.g. inductive loop type
IdId) from a position where the needle is inside the housing to an injection position where the needle projects out of a needle port of the housing on a skin contact face of the housing, and - a plunger actuation mechanism (6) for advancing the plunger for administration of the liquid drug.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/28 - Syringe ampoules or cartridges, i.e. ampoules or cartridges provided with a needle
Provides herein is a method for identifying the specific cell lineage of cells in culture comprising the steps of determining from the nucleic acid molecules isolated from said recombinant cells in culture the presence of polymorphisms or SNPs at at least 5 different positions within at least five genes 5 contained in said nucleic acid molecules, obtaining a genetic profile from the determination of the previous step, and identiyfing the cell lineage of said cells in culture from said genetic profile, and wherein the recombinant cells produce a recombinant protein.
The present invention relates to a method for controlling the afucosylation level of a glycoprotein composition. The method comprises the control of the afucosylation level by selecting the appropriate temperature and/or pH. The invention also relates to glycoprotein compositions produced according to the method of the invention.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention relates to storage containers for electronic injection devices. The storage container comprises a desiccant in airflow communication with an interior space of the storage container, the desiccant being replaceable for continued use of the storage container.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
B65D 81/26 - Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
B65D 81/00 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
A61J 1/00 - Containers specially adapted for medical or pharmaceutical purposes
26.
METHODS FOR MODULATING PROTEIN MANNOSYLATION PROFILES USING A POLYETHER IONOPHORE
The present invention relates to methods and compositions for modulating mannosylation profile of recombinant proteins expressed by mammalian host cells during the cell culture process, using a polyether ionophore.
There is disclosed an interactive patient care system configured to provide care to a patient suffering from a chronic disease or condition, comprising a server system (6) configured to receive and transmit data via a communication network (16) to and from users including 5 patients (15a) and health care professionals (15b). The server system comprises a processing unit (6e), a memory (6f), a patient database (6c) configured to store data related to the patient and a library database (6d) configured to store data related to predefined therapeutic interventions obtained on evidence-based care pathways. The server system further comprises an application server (6b) and a communication server (6a) including a web server 10 software application for data transfer through the internet. The application server (6b) comprises a patient care system software for chronic disease or condition management, configured to: i) select for a given patient at least one predefined therapeutic intervention from the library database based at least on the data related to the patient stored in the patient database, and ii) generate a personalized care plan based at least on the selected predefined 15 therapeutic intervention. The patient care system software comprises patient therapy services (40) comprising health monitoring components (40c) configured to monitor health parameters and/or treatment adherence parameters of the patient. The therapy services are configured to provide health care assistance to the patients based on said personalized care plan.
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
The present invention relates to a method for purifying proteins, such as Fc fusion proteins or antibodies, from a sample comprising said proteins and impurities, through the use of a three- chromatographic columns procedure, including a chromatography on hydroxyapatite- and/or Fluorapatite-containing material. The invention is also concerned with pharmaceutical compositions comprising the purified proteins obtainable by the process of the invention.
A system determines the location of a tip (106) of a hypodermic needle (104) by moving a needle along a path (108), shining light from two sources onto respective portions of the path, and analysing signals received from the respective light sources that have been reflected by the needle.
A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
30.
METHOD AND APPARATUS FOR DETERMINING INFORMATION ABOUT A DRUG-CONTAINING VESSEL
Information about a drug-containing vessel is determined by capturing image data of the curved surface of a cylindrical portion of a drug-containing vessel. The image data is unfurled from around the curved surface, binarised, and a template matching algorithm employed to determine that the label information comprises candidate information about the vessel and/or the drug.
The present invention relates to methods and compositions for culturing a host cell expressing a recombinant protein in a cell culture medium supplemented with feeds comprising effective amounts of valeric acid, whereby viability of the cells and production of said protein are increased relative to cells grown with feeds comprising no valeric acid.
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymes; General processes for the preparation of compounds or compositions by using microorganisms or enzymes
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
32.
METHODS FOR MODULATING PROTEIN GALACTOSYLATION PROFILES OF RECOMBINANT PROTEINS USING PERACETYL GALACTOSE
The present invention relates to methods and compositions for modulating glycosylation profile, such as the galactosylation profile, of recombinant proteins expressed by mammalian host cells during the cell culture process by supplementing cell culture media with a peracetyl galactose.
The invention relates to a method for determining the clonality of a master cell bank (MCB) in which a transgene has been inserted. The method involves a combination of sequencing methodology and bioinformatic analysis, performed on multiple subclones originating from a common MCB, to establish a reliable set of reference transgene insertion regions in one reference subclone, and corresponding sets of comparative transgene insertion regions in one or more other subclones originating from the same MCB. Based on the degree of congruity between reference and comparative transgene insertion regions, the MCB is determined to be either monoclonal or polyclonal.
The present invention relates to methods and compositions for modulating glycosylation of recombinant proteins expressed by mammalian host cells during the cell culture process. Also 5 disclosed are methods of culturing a host cell expressing a recombinant protein in a cell culture medium comprising a disaccharide or a trisaccharide, while keeping the osmolality constant.
The invention is in the field of cell culture. Particularly the invention relates to methods of culturing a mammalian host cell expressing a recombinant protein in perfusion mode, using a concentrated cell culture medium.
The invention is in the field of cell culture. Particularly the invention relates to methods of culturing a host cell expressing a recombinant protein in a cell culture medium comprising an effective amount of 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) or supplemented with an effective amount of DIDS, whereby production of said protein is increased relative to cells grown without DIDS.
The invention is in the field of cell culture. Particularly the invention relates to methods of culturing a host cell expressing a recombinant protein in a cell culture medium comprising an effective amount of a triazine dye or supplemented with an effective amount of a triazine dye, whereby production of said protein is increased relative to cells grown without said triazine dye or any other inducer.
The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.
The present invention relates to methods and compositions for modulating glycosylation profile of recombinant proteins expressed by mammalian host cells during the cell culture process by supplementing cell culture media with a trisaccaride.
The invention relates to a multiple-variable dose method for treating a disorder in which TNFα activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNFα antibody which ranges from 161 to 320 mg such that a threshold level of TNFα inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNFα inhibitor within a treatment phase, such that treatment occurs
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Patient care system comprising a medical device (1) for administering a medical treatment to a patient (15a) and a server system (6) configured to receive and transmit data via a communications network (16) to, respectively from users including patients (15a) and health care professionals (15b), the server system further configured to process and store data related to patient care. The server system comprises a database (6c) configured to encrypt and store encrypted data related to patient care, an application server (6b) including patient care software components for disease management (36) and patient information management (32), a communication server (6a) including a web server software application for data transfer through the internet, the patient care software components operable to receive medical device usage data comprising data on the usage of said medical device transferred through the communications network, and further operable to process said medical device usage data in conjunction with patient data (32c) to generate a report (32f) or a plurality of reports related to the treatment of the patient, the reports being accessible remotely via the communications network by registered users of the patient care system as a function of respective roles and privileges of the registered user stored in the server system.
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
The present invention relates to a novel melatonin-based formulation, particularly a topical liquid composition of melatonin (or analog thereof) suitable for use in intrauterine washing performed during medically assisted reproduction (e.g. in vitro fertilisation - IVF). Melatonin is notoriously unstable, especially in solution. The compositions of the invention exhibit high stability, which allows them to be kept for prolonged periods before their eventual use in the inhibition or prevention of embryonic implantation failure.
The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, and at least one component selected from the group consisting of: a polyvinylpyrrolidone (PVP) surfactant, an inositol sugar stabiliser, and a gluconate salt toncifier. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
The present invention relates to immunoassays for quantification of a high positively charged protein, such as a FGF-18 protein, in human synovial fluid sample.
The present invention relates to novel liquid protein formulations, particularly arginine-free liquid pharmaceutical compositions of etanercept. The invention employs particular combinations and classes of buffer systems, tonicifiers, and sugar stabilisers, optionally alongside polar ionisable amino acids (e.g. aspartic acid, glutamic acid, histidine, and lysine), to afford a viable and storable drug product.
The present invention relates to the use of 2-aminobenzamide (2-AB) for labelling saccharolipids, as well as to methods of labelling saccharolipids with 2-AB. It also describes methods of identifying, detecting, characterizing or analysing saccharolipids in a sample, once labelled with 2-AB. Such uses and methods have their place as analytical methods when it is needed to analyse saccharolipids containing medicinal, biological or cosmetic samples, for instance. The use and methods herein described aim at facilitating identification and analysis of saccharolipids. The saccharolipid compounds contain four to seven fatty acyl chains.
The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, a citrate buffering agent/system such as sodium citrate/citric acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/19 - Particulate form, e.g. powders lyophilised
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
The present invention provides a composition comprising an interferon-beta (IFN-beta) protein of which at least 80% is deamidated, a deamidated IFN-5 beta 1a protein, methods of producing deamidated proteins, and therapeutic uses of such compositions and deamidated IFN-beta 1a proteins.
The invention relates to the field of pharmaceutical formulations. More particularly it is directed to xyloglucan hydrogels comprising Fibroblast Growth Factor 18 (FGF-18) compound and to methods of producing such hydrogels. The hydrogels of the invention can be used, once formed in situ, for the treatment of cartilage disorders such as osteoarthritis or cartilage injury.
The invention relates to the field of pharmaceutical formulations. More particularly it is directed to homogeneous hydrogels comprising Fibroblast Growth Factor 18 (FGF-18) compound and to methods of producing such hydrogels. The hydrogels of the invention can be used, once formed in situ, for the treatment of cartilage disorders such as osteoarthritis or cartilage injury.
A medical device connection station comprising a body having a first portion of a docking interface to dock with a corresponding second portion of a docking interface of a medical device, a control unit controlling a medical device communication interface for communication with a docked medical device and controlling a server communication interface. The control unit is configured acquire medical data from a docked medical device via the medical device communication interface and is further configured to connect with and obtain a data session with the server system via the server communication interface, and to thereby transfer the medical data to the server system. The medical device connection station further comprises a lid connected to the body and movable between a first and second position, wherein in the first position the lid prevents first portion of the docking interface from docking with the second portion of the docking interface of the medical device, and wherein in the second position the first portion of the docking interface is operable to dock with the second portion of the docking interface. The medical device connection station comprises a lid movement sensing unit which is configured to sense movement of the lid between the first position and the second position and to thereby provide a signal to the control unit, the control unit configured to receive the signal to initiate the connection to the server system.
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
G06F 1/16 - Constructional details or arrangements
54.
A LIQUID FORMULATION OF A FUSION PROTEIN COMPRISING TNFR AND FC REGION
The present invention relates to a liquid formulation comprising a TNFR-Fc fusion protein and a stabilizer, in which the fusion protein comprises TNFR (tumor necrosis factor receptor) or a fragment thereof and an immunoglobulin Fc region, and the stabilizer comprises one or more amino acids selected from the group consisting of proline and histidine, a buffer solution, and an isotonic agent containing sodium chloride (NaCl) and sucrose, and a preparation method of the liquid formulation. The liquid formulation according to the present invention provides excellent storage stability because long-term storage of TNFR-Fc fusion protein (etanercept) is possible and particular storage conditions are not needed. Since the liquid formulation of the present invention shows excellent storage stability even though the formulation is simple, it is more economical than other stabilizers or lyophilized formulations, and thus the formulation can be effectively applied for uses wherein treatment of TNFR-Fc fusion protein (etanercept) is beneficial.
The injection device (1, 10) comprises a medicine container, means for injecting medicine from the medicine container to a patient through a needle, a skin contact surface (10b) crossable by the needle and having protrusions (14) which are pressed around the injection site when the injection device (1, 10) is applied on the patient's skin for the injection, the protrusions (14) being arranged so as to reduce the pain caused by the penetration of the needle, and a sensor for detecting contact of the patient's skin with the skin contact surface (10b), wherein a predetermined force of application of the injection device (1, 10) on the patient's skin is required for the sensor to detect the patient's skin. According to another aspect of the invention, the protrusions (14) include first and second protrusions (14a, 14b), wherein the first protrusions (14a) come into contact with the patient's skin as the device is applied with a first force and the second protrusions (14b) come into contact with the patient's skin as the device is applied with a second force, the second force being greater than the first force.
A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
56.
PATIENT CARE SYSTEM REPORTING ADHERENCE TO TREATMENT REGIMEN
Patient care system comprising a medical device (1) for administering a medical treatment to a patient (15a) and a server system (6) configured to receive and transmit data via a communications network (16) to, respectively from users including patients (15a) and health care professionals (15b), the server system further configured to process and store data related to patient care. The server system comprises a database (6c) configured to encrypt and store encrypted data related to patient care, an application server (6b) including patient care software components for disease management (36) and patient information management (32), a communication server (6a) including a web server software application for data transfer through the internet, the patient care software components operable to receive medical device usage data comprising data on the usage of said medical device transferred through the communications network, and further operable to process said medical device usage data in conjunction with patient data (32c) to generate a report (32f) or a plurality of reports related to the treatment of the patient, the reports being accessible remotely via the communications network by registered users of the patient care system as a function of respective roles and privileges of the registered user stored in the server system.
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
57.
NEW MEDIUM FOR HIGH PERFORMANCE MAMMALIAN FED-BATCH CULTURES
The present invention relates to new serum-and protein-free culture media. These media are high performance culture media, which notably improve mammalian fed-batch cultures. The present invention also relates to methods for preparing and/or designing the medium, and methods of use thereof.
The invention relates to monoclonal antibodies against human CXCR5 and to their use in the treatment of autoimmune or inflammatory diseases, as well as cancers.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
59.
FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS
The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The injection device comprises: a static structure (2) comprising a first gear member (14), a dynamic structure (3) comprising a medicine container (11), means (6, 7, 8, 12) for pushing liquid medicine out of said medicine container (11) for its injection to a patient, and a second gear member (13) engaged with the first gear member (14), a drive member (4) for driving one (14) of the first and second gear members (13, 14) so as to cause the dynamic structure (3) to move relative to the static structure (2) along a predetermined direction (D) due to the engagement between the first and second gear members (13, 14), and clutch means (23, 25, 28) for maintaining engagement between the first and second gear members (13, 14) in normal condition of the injection device, and for allowing disengagement of the first and second gear members (13, 14) upon a shock received by the injection device along the predetermined direction (D).
An injection device for injecting liquid medicine to a patient comprises a medicine container (2) an end of which is connectable to a needle (3) and magnetic sensor means (21, 22) for sensing connection of the needle (3) to the medicine container (2).
An injection device for injecting liquid medicine to a patient comprises a main part (13) and a removable module (14), wherein the main part is arranged to house a medicine container (11) connected to a needle (9) and the removable module comprises a skin contact surface (10), the skin contact surface having a through hole (8) for passage of the needle and being intended to rest on the patient's skin during the injection.
A61K 31/4427 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 25/00 - Drugs for disorders of the nervous system
A61K 31/547 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
66.
USE OF N-ACETYL-5-METHOXYTRYPTAMINE OR ANALOGUES THEREOF, FOR PROMOTING THE MECHANISM OF IMPLANTATION OF THE EMBRYO AND RELATED COMPOSITIONS AND CULTURE MEDIA
The present invention refers to the use of N-acetyl-5-methoxytryptamine (melatonin) and/or an analogue thereof, for use in the medical or veterinary field in the assisted reproduction for promoting the mechanism of implantation of the embryo, and in particular for the prevention of implantation failure into the uterus, by topical administration of an effective amount in a mammalian subject female in need of such treatment, and related compositions, culture media and medical devices.
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/4045 - Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
A61P 15/08 - Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61K 9/00 - Medicinal preparations characterised by special physical form
A61B 17/42 - Gynaecological or obstetrical instruments or methods
The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases. In formula (I), Rb and Rc are independently selected from one another from H or C1-C6-alkyl; whereby Rb and Rc may be linked to form a 5 or 6 membered-ring containing the oxygen atoms to which they are linked; Q denotes Ar, Het or cycloalkyl; R1 R2 independently from each other denotes H, ORa, Hal, C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; Y denotes CR 3R4, preferably CH2 or C(CH3)2; R 3, R4 independently of one another denote H or C1-C6-alkyl; L denotes L1 or L2 or alkyl; n is an integer selected from 0 to 3; L 1 is Q1-CO-M- wherein Q 1 is Ar or Het, preferably, phenyl, naphthyl or pyridine, optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; L2 is Q2-M- wherein Q 2 is a fused bicyclic system containing 1 nitrogen atom and 1 to 3 additional groups independently selected from O, S, N, or CO, and wherein at least one of the rings is aromatic whereby the fused bicyclic system is optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; or Q 2 is unsaturated or aromatic 5 membered-ring system containing 1 to 3 heteroatoms selected from N, O, S and CO, and optionally substituted with a phenyl ring or pyridine ring whereby phenyl ring and pyridine ring are optionally substituted with 1 to 4 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; M is a linear or branched alkylene having 1 to 5 carbon atoms wherein 1 or 2 H atoms may be replaced by OR a or a phenyl ring optionally substituted with 1 to 5 groups independently selected from Hal, ORa, and C1-C6-alkyl optionally substituted with 1 to 5 groups independently selected from OH, and Hal; or M denotes a cycloalkylene having 3 to 7 carbon atoms; or M denotes a thiazolidinyl group; R a is H or C1-C6-alkyl wherein 1 to 5 H atom may be independently replaced by OH or Hal; Ar denotes a 6 membered-aromatic carbocyclic ring optionally fused with another carbocyclic saturated, unsaturated or aromatic ring having 5 to 8 carbon atoms; Het denotes a 5- or 6-membered saturated, unsaturated or aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from N, N+O-, O, S, SO, and SO 2, and optionally fused with another saturated, unsaturated or aromatic ring having 5 to 8 atoms and optionally containing 1 to 3 heteroatoms selected from N, O, and S; Hal denotes CI, Br, I of F; preferably CI or F.
The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/26 - Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The present invention provides a method for the purification of immunoproteasomes comprising subjecting an immunoproteasome solution to hydrophobic interaction chromatography, wherein the hydrophobic interaction chromatography is performed with a resin comprising butyl residues.
The invention relates to the field of pharmaceutical formulations. More particularly it is directed to freeze-dried formulations of Fibroblast Growth Factor 18 (FGF-18) compound and to methods of producing such formulations. The freeze-dried formulations according to the invention are stable upon storage for an appropriate period of time. They can be used, after reconstitution, for the treatment of cartilage disorders such as osteoarthritis or cartilage injury.
The present invention pertains to interferon-beta (IFN-beta) compositions comprising interferon-beta and a grafted poly(glutamic acid) polymer having an average molecular weight between 26 000 and 40 000 g/mol, grafted with alpha-tocopherol substituants, the average molar grafting ratio being 4.5 - 5.5 moles %, the weight/weight ratio between said grafted poly(glutamic acid) polymer and IFN-beta being between 24 and 125. The present invention also pertains to the preparation methods of such compositions and their application to obtain therapeutic compositions in dosage unit form delivering IFN-beta over an extended period of time.
The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
The present invention is directed to compounds of Formula (I) below, which are antagonists to the chemoattractant cytokine receptor 2 (CCR2), and/or 5 (CCR5), pharmaceutical compositions, and methods for use thereof.
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
74.
METHODS FOR IMPROVING THE DESIGN, BIOAVAILABILITY, AND EFFICACY OF DIRECTED SEQUENCE POLYMER COMPOSITIONS VIA SERUM PROTEIN-BASED DETECTION OF DIRECTED SEQUENCE POLYMER COMPOSITIONS
There exist in the art methods of detecting simple peptides. However, methods to determine the effective plasma concentration of directed sequence polymers (DSPs), are complicated because DSPs are complex mixtures of peptides, as opposed to individual peptides with a defined amino acid sequence. This application provides improved methods of detecting and assessing DSP compositions, methods for the detection and quantitation of DSP compositions, means to determine and enrich a subset of peptides in a DSP composition based on the subset's interactions with certain capture polypeptides, and methods for administering DSP compositions to a subject in need thereof, wherein the dosage regimen and quantity may be determined or evaluated based on the above- mentioned methods for detection and quantitation.
C07K 4/00 - Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
75.
METHODS FOR IMPROVING THE DESIGN, BIOAVAILABILITY, AND EFFICACY OF RANDOM SEQUENCE POLYMER COMPOSITIONS VIA SERUM PROTEIN-BASED DETECTION OF RANDOM SEQUENCE POLYMER COMPOSITIONS
There exist in the art methods of detecting simple peptides. However, methods to determine the effective plasma concentration of mixtures of peptides as a group, rather than for individual peptides with a defined amino acid sequence, are complicated by the heterogeneity of the peptides to be detected. This application provides improved methods of detecting and assessing random sequence polymer (RSP) compositions, methods for the detection and quantitation of RSP compositions, means to determine and enrich a subset of peptides in an RSP composition based on the subset's interactions with certain capture polypeptides, and methods for administering RSP compositions to a subject in need thereof, wherein the dosage regimen and quantity may be determined or evaluated based on the above-mentioned methods for detection and quantitation.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
79.
COMBINATION OF BLYS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE
The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/00 - Drugs for immunological or allergic disorders
80.
USE OF TACI-IG FUSION PROTEIN SUCH AS ATACICEPT FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING LUPUS ERYTHEMATOSUS
In various embodiments, the present invention provides methods, compositions, dosing, and administration schedules for treatment of autoimmune diseases, including systemic erythematosus (SLE), for example, comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule such as atacicept. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BLyS and APRIL, in particular the use of multiple administrations of the fusion molecule at relatively low dose over the course of the treatment.
The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G01N 33/483 - Physical analysis of biological material
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
The present invention provides methods of treating a subject suffering from multiple myeloma comprising administering to the subject an effect amount of a compound according to Formula I:
This invention relates to novel proteins (termed INSP 176, INSP 177 and INSP 178), herein identified as immunoglobulin domain-containing cell surface recognition molecules and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.
The present invention provides methods of treating a subject with non- alcoholic fatty liver disease (NAFLD), insulin resistance, obesity or hyperlipidemia, comprising administering to the subject an effective amount of a compound according to Formula (I): or a physiologically acceptable salt thereof.
A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
The invention is based on the discovery that the human proteins referred to herein as INSP216, INSP216sv1, INTP216sv2 and INSP216 var are SUSHI domain-containing proteins.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The invention relates to a process for the purification of an Fc-fusion protein having a pI between 6.9 and 9.5 comprising protein A or G affinity chromatography, cation exchange chromatography, anion exchange chromatography and hydroxyapatite chromatography.
The invention relates to a process for reducing the concentration of free Fc- moieties in a fluid comprising an Fc-containing protein comprising a cation exchange chromatography step.
The invention relates to a device (1) for overturning containers (2), particularly roller bottles intended for cell cultures, characterized in that it comprises a rotation actuator (3) associated by means of a transmission shaft (13) to a reducer (4) and a dynamic brake (5), a support (17) and rods (7) gripping the container (2), said support (17) being joined to the rotation actuator (3) by means of a shifter (16) of the transmission shaft (13) of the mentioned rotation actuator (3), the rotation actuator (3) being actuated by means of a pneumatic foot pedal (18), and the mentioned rotation actuator (3) in turn being associated to a timer (19) indicating the end of the overturning time of the container (2).
This invention concerns the treatment of cartilage disorder and osteoarthritis in particular. More specifically, it relates to the use of FGF-18 in treatment regimens and for the manufacture of a medicament for the treatment of patients having a cartilage disorder such as osteoarthritis, such as for example knee osteoarthritis or secondary hip osteoarthritis. Specifically provided is a preferred treatment scheme comprising once weekly administration of an FGF-18 compound per treatment cycle.
This invention relates to novel proteins, termed INSP 193, and INSP 194, herein identified as secreted proteins that contain a Vault protein inter-alpha-trypsin (VIT) domain and a von Willebrand factor A type domain, and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
92.
INTEGRAL MEMBRANE PROTEIN OF THE PMP-22/EMP/MP20/ CLAUDIN-LIKE FAMILY
This invention relates to a novel protein, termed INSP219, herein identified as a protein, in particular, as a PMP-22/EMP/MP20/Claudin-like molecule and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
This invention relates to a protein (INSP 192) herein identified as a GPI-anchored, cell surface glycoprotein and to INSP 195, a splice variant and soluble form of INSP 192 and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
This invention relates to protein INSP 185, herein identified as a novel secreted protein, in particular as a secreted protein homologous to PRO4426, and to the use of this protein and the nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
This invention relates to a protein, termed INSP191, herein identified as a secreted protein, in particular, as a complement protein and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
This invention relates to a protein, termed INSP 189, herein identified as a secreted protein, in particular, as a member of the four helical bundle cytokine family, and more particularly as an IL-22 like protein and to the use of this protein and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
An oral pharmaceutical composition comprising a capsule dosage form containing a liquid fill composition including an anilinopyrimidine derivative of Formula (I) and a pharmaceutically acceptable excipient selected from the group consisting of polyethylene glycol, a glyceryl ester of capric acid or a mixture thereof. The liquid fill composition is formulated in a hard gelatin capsules and can be used for the preparation of a medicament for the treatment of cancer in particular AML.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
98.
MEMBERS OF THE GLYCOSIDE HYDROLASE FAMILY 31 FAMILY OF PROTEINS
This invention relates to novel proteins, termed INTP041, INTP042 and INTP043, herein identified as members of the glycoside hydrolase family 31 family of proteins and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.
This invention relates to a novel protein, termed INSP 190, herein identified as a secreted protein, in particular, as a CD24-like protein and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BIyS and APRIL.